Pacific Software Inc. Obtaining Quotes for the Manufacturing Cycle for Scientifically Tested Medical Food Cocktail Focused on Memory Health
Pacific Software announced the acquisition of a dietary supplement designed to support brain health and memory, marketed as SuppleMEM AD™ and A.L.Z. Defense™.
The formula, tested by leading Alzheimer's researchers, has been sold for over 8 years. The company is obtaining quotes to manufacture this product in the USA and Mexico, targeting distribution in the third quarter of 2024.
This acquisition aligns with Pacific's strategy to diversify into health and skin care products. The core formula, a blend of natural ingredients, has shown positive results in NIH-funded studies at UC Irvine and the University of Kentucky.
The company expects revenue from retail and wholesale channels. Dr. Leissring resigned as president on June 18, 2024.
- Acquisition of a scientifically-tested product with over 8 years on the market.
- Potential revenue from both retail and wholesale distribution channels.
- Strategic expansion into the health and memory support sector.
- Resignation of Dr. Leissring as president on June 18, 2024.
DANA POINT, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Pacific Software Inc. ("Pacific" or “Company”) on May 24 2024, the Company announced the acquisition of a science-based dietary supplement supporting brain health and memory function. The supplement, which has been sold for more than 8 years under the brand names SuppleMEM AD™ and A.L.Z. Defense™, features a formula tested extensively by leading Alzheimer's researchers. Through a consultant based in Mexico, we are currently in the process of obtaining quotes in order to manufacture this product and distribute it throughout Mexico.
"Acquiring this established product line not only adds another path to expected profitability for Pacific, but it also signifies a strategic expansion of our business model," said Harrysen Mittler, CEO. Prior to this acquisition, the Company had been focused primarily on the cosmetics and skin care sectors, having licensed a patented technology for stimulating collagen production for skin care and wound healing. "Though we remain focused on scientifically validated products, a business environment encompassing both health and skin care is a natural fit."
The core formula within A.L.Z. Defense™ is a combination of safe, natural products combined into a single "medical food cocktail" specifically formulated to support essential aspects of memory such as neuroplasticity. The formula was evaluated in two large, multi-year laboratory experiments funded by a grant from the National Institutes of Health (NIH). The first study, conducted at the University of California, Irvine, was performed in a mouse model of Alzheimer’s disease. The second study, conducted at the University of Kentucky, tested the formula in dogs (beagles) which develop the disease late in life. Both studies were conducted by highly reputable groups of Alzheimer's researchers. Citations for the publications describing the results of these studies are provided below.
The Company is currently in the process of receiving production quotations in order to manufacture the A.L.Z Defense ™ in the USA and Mexico and expects the distribution of the product in both countries to commence in the 3rd quarter of 2024. Once the Company receives these quotes it will conduct its review and decide on the final manufacturers; thereafter. Revenues are anticipated in both the retail and wholesale sectors via online sales and established distribution channels on the wholesale level. Further, it is believed that Alzheimer's disease can be mitigated through lifestyle changes, nutrition and dietary supplements. On June 18, 2024, Dr. Leissring resigned as president of the Company.
References
- Parachikova A, Green KN, Hendrix C, LaFerla FM. PLoS One. 2010 Nov 17;5(11):e14015. doi: 10.1371/journal.pone.0014015. PubMed PMID: 21103342; PubMed Central PMCID: PMC2984445.
- Head E, Murphey HL, Dowling AL, McCarty KL, Bethel SR, Nitz JA, Pleiss M, Vanrooyen J, Grossheim M, Smiley JR, Murphy MP, Beckett TL, Pagani D, Bresch F, Hendrix C. J Alzheimers Dis. 2012;32(4):1029-42. doi: 10.3233/JAD-2012-120937. PubMed PMID: 22886019; PubMed Central PMCID: PMC4006672.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, PFSF's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various scientific and manufacturing programs, changes in future customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond PFSF's control. Except as may be required by law, Pacific Software, Inc. undertakes no obligation, and does not intend, to update these forward-looking statements after the date of this release.
Contact:
Harrysen Mittler, CEO
Tel: (310) 600-5064
E-mail: info@pacificsoftwareinc.com
Website: pacificsoftwareinc.com
Source: Pacific Software Inc.
FAQ
What product did Pacific Software acquire for brain health?
When will Pacific Software start distributing A.L.Z. Defense?
Which studies support the effectiveness of A.L.Z. Defense?
What impact does the acquisition have on Pacific Software's business model?
When did Dr. Leissring resign as president of Pacific Software?
